High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: Interaction with IQ motif-containing factors

Cell Cycle

Volumn 12, Issue 18, 2013, Pages 3013-3024

  Robinson, Tyler Jw ^a   Pai, Melody ^b   Liu, Jeff C ^a   Vizeacoumar, Frederick ^c   Sun, Thomas ^c   Egan, Sean E ^d   Datti, Alessandro ^c,e   Huang, Jing ^b   Zacksenhaus, Eldad ^a,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cancer stem cells; Disulfiram; High throughput screens; IQGAP1; Keywords: triple negative breast cancer; MYH9

Indexed keywords

DISULFIRAM; DOXORUBICIN; GEMCITABINE; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; PACLITAXEL; PALBOCICLIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL AGING; CELL DEATH; CELL GROWTH; CELL POPULATION; DRUG EFFICACY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; TRIPLE NEGATIVE BREAST CANCER;

CANCER STEM CELLS; DISULFIRAM; HIGH-THROUGHPUT SCREENS; IQGAP1; MYH9; TRIPLE-NEGATIVE BREAST CANCER;

ANTIGENS, CD24; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION MOLECULES; CELL AGING; CELL LINE, TUMOR; DISULFIRAM; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MCF-7 CELLS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; NEOPLASTIC STEM CELLS; PROTEIN BINDING; RAS GTPASE-ACTIVATING PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84884878213     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26063     Document Type: Article

References (91)

1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16(Suppl 1):61-70; PMID:21278442; http://dx.doi.org/10.1634/ theoncologist.2011-S1-61
2. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, et al. RB1 and p53 at the crossroad of EMT and triplenegative breast cancer. Cell Cycle 2011; 10:1563-70; PMID:21502814; http://dx.doi.org/10.4161/cc.10.10.15703
3. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27; PMID:17157791; http://dx.doi.org/10.1016/j.ccr.2006.10.008
4. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7:687-93; PMID:8905026; http://dx.doi.org/10.1093/ oxfordjournals.annonc. a010717
5. van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics 2013; 14:799-811; PMID:23651027; http://dx.doi.org/10.2217/pgs. 13.54
6. von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother 2007; 8:485-95; PMID:17309343; http://dx.doi.org/10.1517/14656566.8.4.485
7. Kadakia A, Rajan SS, Abughosh S, Du XL, Johnson ML. CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-medicare-based population study. Am J Clin Oncol 2013; PMID:23608830; http://dx.doi.org/10.1097/COC.0b013e31828f5b01
8. Zare N, Ghanbari S, Salehi A. Effects of two chemotherapy regimens, anthracycline-based and CMF, on breast cancer disease free survival in the Eastern Mediterranean Region and Asia: a meta-analysis approach for survival curves. Asian Pac J Cancer Prev 2013; 14:2013-7; PMID:23679310; http://dx.doi.org/10.7314/APJCP.2013.14.3.2013
9. O'Shaughnessy JA, Fisherman JS, Cowan KH. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol 1994; 21(Suppl 8):19-23; PMID:7939757
10. Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, et al. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma 2012; 59:38-42; PMID:22103897; http://dx.doi.org/10.4149/neo-2012-005
11. Kohail H, Shehata S, Mansour O, Gouda Y, Gaafar R, Hamid TA, El Nowieam S, Al Khodary A, El Zawahry H, Wareth AA, et al. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. Hematol Oncol Stem Cell Ther 2012; 5:42-8; PMID:22446614
12. Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol 2012; 23(Suppl 6):vi40-5; PMID:23012301; http://dx.doi.org/ 10.1093/annonc/mds194
13. Dalvi RR. Toxicology of thiram (tetramethylthiuram disulfide): a review. Vet Hum Toxicol 1988; 30:480-2; PMID:3055654
14. Christensen JK, Møller IW, Rønsted P, Angelo HR, Johansson B. Dose-effect relationship of disulfiram in human volunteers. I: Clinical studies. Pharmacol Toxicol 1991; 68:163-5; PMID:2057446; http://dx.doi.org/10. 1111/j.1600-0773.1991.tb01215.x
15. Cornford EM, Bocash WD, Braun LD, Crane PD, Oldendorf WH, MacInnis AJ. Rapid distribution of tryptophol (3-indole ethanol) to the brain and other tissues. J Clin Invest 1979; 63:1241-8; PMID:447842; http://dx.doi.org/10.1172/ JCI109419
16. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009; 15:6070-8; PMID:19789329; http://dx.doi.org/10.1158/1078-0432.CCR-09-1035
17. Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 2012; 3:1124-36; PMID:23165409
18. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget 2012; 3:1112-23; PMID:23047041
19. Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets 2011; 11:332-7; PMID:21247389; http://dx.doi.org/10.2174/156800911794519806
20. Kast RE, Boockvar JA, Brüning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 2013; 4:502-30; PMID:23594434
21. Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP, Wu G. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 2010; 70:3996-4004; PMID:20424113; http://dx.doi.org/10.1158/0008-5472.CAN-09-3752
22. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL, Wang W. Disulfiram modulated ROS-MAPK and NFkB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 2011; 104:1564-74; PMID:21487404; http://dx.doi.org/10.1038/bjc.2011.126
23. Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol Biosyst 2005; 1:127-34; PMID:16880974; http://dx.doi.org/10.1039/b504392a
24. Liu GY, Frank N, Bartsch H, Lin JK. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins. Mol Carcinog 1998; 22:235-46; PMID:9726816; http://dx.doi.org/10.1002/(SICI)1098- 2744(199808)22:43.0.CO;2-I
25. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13(8B):2236-52; PMID:18681906; http://dx.doi.org/10.1111/j.1582- 4934.2008.00455.x
26. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29:32-45; PMID:21280157; http://dx.doi.org/10. 1002/stem.563
27. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, Wang J, Wu RP, Gomez F, Loo JA, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A 2009; 106:21984-9; PMID:19995983; http://dx.doi.org/10.1073/pnas.0910040106
28. Lomenick B, Jung G, Wohlschlegel JA, Huang J. Target identification using drug affinity responsive target stability (DARTS). Curr Protoc Chem Biol 2011; 3:163-80; PMID:22229126
29. Lomenick B, Olsen RW, Huang J. Identification of direct protein targets of small molecules. ACS Chem Biol 2011; 6:34-46; PMID:21077692; http://dx.doi.org/10.1021/cb100294v
30. Wang JB, Sonn R, Tekletsadik YK, Samorodnitsky D, Osman MA. IQGAP1 regulates cell proliferation through a novel CDC42-mTOR pathway. J Cell Sci 2009; 122:2024-33; PMID:19454477; http://dx.doi.org/10.1242/jcs.044644
31. Meyer RD, Sacks DB, Rahimi N. IQGAP1- dependent signaling pathway regulates endothelial cell proliferation and angiogenesis. PLoS One 2008; 3:e3848; PMID:19050761; http://dx.doi.org/10.1371/journal.pone.0003848
32. Kozlova I, Ruusala A, Voytyuk O, Skandalis SS, Heldin P. IQGAP1 regulates hyaluronan-mediated fibroblast motility and proliferation. Cell Signal 2012; 24:1856-62; PMID:22634185; http://dx.doi.org/10.1016/j.cellsig.2012.05.013
33. Johnson MA, Henderson BR. The scaffolding protein IQGAP1 co-localizes with actin at the cytoplasmic face of the nuclear envelope: implications for cytoskeletal regulation. Bioarchitecture 2012; 2; PMID:22964981; http://dx.doi.org/10.4161/bioa.21182
34. Briggs MW, Sacks DB. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep 2003; 4:571-4; PMID:12776176; http://dx.doi.org/10.1038/sj.embor.embor867
35. Hosono Y, Usukura J, Yamaguchi T, Yanagisawa K, Suzuki M, Takahashi T. MYBPH inhibits NM IIA assembly via direct interaction with NMHC IIA and reduces cell motility. Biochem Biophys Res Commun 2012; 428:173-8; PMID:23068101; http://dx.doi.org/10.1016/j.bbrc.2012.10.036
36. Raab M, Swift J, Dingal PC, Shah P, Shin JW, Discher DE. Crawling from soft to stiff matrix polarizes the cytoskeleton and phosphoregulates myosin-II heavy chain. J Cell Biol 2012; 199:669-83; PMID:23128239; http://dx.doi.org/10. 1083/jcb.201205056
37. Yang F, Wei Q, Adelstein RS, Wang PJ. Non-muscle myosin IIB is essential for cytokinesis during male meiotic cell divisions. Dev Biol 2012; 369:356-61; PMID:22820068; http://dx.doi.org/10.1016/j.ydbio.2012.07.011
38. Bähler M, Rhoads A. Calmodulin signaling via the IQ motif. FEBS Lett 2002; 513:107-13; PMID:11911888; http://dx.doi.org/10.1016/S0014-5793(01)03239- 2
39. Stuart DD, Sellers WR. Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer. Nat Med 2013; 19:538-40; PMID:23652103; http://dx.doi.org/10.1038/ nm.3195
40. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5:e13984; PMID:21085593; http://dx.doi.org/10.1371/journal.pone. 0013984
41. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 1999; 18:7034-45; PMID:10597304; http://dx.doi.org/10.1038/sj.onc.1203183
42. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001; 10:237-42; PMID:11159942; http://dx.doi.org/10.1093/hmg/10.3.237
43. Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277:25847-50; PMID:12011103; http://dx.doi.org/10.1074/jbc.R200008200
44. Kartal Yandim M, Apohan E, Baran Y. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer. Cancer Chemother Pharmacol 2013; 71:13-20; PMID:23073611; http://dx.doi.org/10.1007/s00280-012-1984-x
45. Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R, Botti J, Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem 2006; 281:8518-27; PMID:16415355; http://dx.doi.org/10.1074/jbc.M506182200
46. Okamoto H, Takuwa N, Gonda K, Okazaki H, Chang K, Yatomi Y, Shigematsu H, Takuwa Y. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem 1998; 273:27104-10; PMID:9765227; http://dx.doi.org/10.1074/jbc.273.42.27104
47. Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM. Role of ceramide in cellular senescence. J Biol Chem 1995; 270:30701-8; PMID:8530509; http://dx.doi.org/10.1074/jbc.270.51.30701
48. Sultan A, Ling B, Zhang H, Ma B, Michel D, Alcorn J, Yang J. Synergistic effect between sphingosine- 1-phosphate and chemotherapy drugs against human brain-metastasized breast cancer MDA-MB-361 cells. J Cancer 2013; 4:315-9; PMID:23569464; http://dx.doi.org/10.7150/jca.5956
49. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006; 25:7305-10; PMID:16785993; http://dx.doi.org/10.1038/sj.onc.1209735
50. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA, Holt SE. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277:35509-15; PMID:12101184; http://dx.doi.org/10.1074/jbc.M205477200
51. Jackson JG, Pant V, Li Q, Chang LL, Quintás- Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21:793-806; PMID:22698404; http://dx.doi.org/10.1016/j.ccr.2012.04. 027
52. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 2003; 100:3547-9; PMID:12657737; http://dx.doi.org/10.1073/pnas.0830967100
53. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730
54. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324:1670-3; PMID:19556499; http://dx.doi.org/10.1126/ science.1171837
55. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A, Berti P, Carpi A, Miccoli P. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol 2011; 12:196-205; PMID:21044007; http://dx.doi.org/10.2174/138920111794295657
56. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas. 0530291100
57. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10:R25; PMID:18366788; http://dx.doi.org/10.1186/bcr1982
58. Casteel DE, Turner S, Schwappacher R, Rangaswami H, Su-Yuo J, Zhuang S, Boss GR, Pilz RB. Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration. J Biol Chem 2012; 287:38367-78; PMID:22992742; http://dx.doi.org/10.1074/jbc.M112.377499
59. Hayashi H, Nabeshima K, Aoki M, Hamasaki M, Enatsu S, Yamauchi Y, Yamashita Y, Iwasaki H. Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis-critical role in tumor invasion. Int J Cancer 2010; 126:2563-74; PMID:19856315
60. Jadeski L, Mataraza JM, Jeong HW, Li Z, Sacks DB. IQGAP1 stimulates proliferation and enhances tumorigenesis of human breast epithelial cells. J Biol Chem 2008; 283:1008-17; PMID:17981797; http://dx.doi.org/10.1074/jbc. M708466200
61. Johnson M, Sharma M, Henderson BR. IQGAP1 regulation and roles in cancer. Cell Signal 2009; 21:1471-8; PMID:19269319; http://dx.doi.org/10.1016/j. cellsig.2009.02.023
62. Liu Z, Liu D, Bojdani E, El-Naggar AK, Vasko V, Xing M. IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res 2010; 16:6009-18; PMID:20959410; http://dx.doi.org/10.1158/1078-0432.CCR-10-1627
63. Walch A, Seidl S, Hermannstädter C, Rauser S, Deplazes J, Langer R, von Weyhern CH, Sarbia M, Busch R, Feith M, et al. Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod Pathol 2008; 21:544-52; PMID:18246045; http://dx.doi.org/10.1038/modpathol.2008.3
64. White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009; 583:1817-24; PMID:19433088; http://dx.doi.org/10.1016/j.febslet.2009.05.007
65. White CD, Erdemir HH, Sacks DB. IQGAP1 and its binding proteins control diverse biological functions. Cell Signal 2012; 24:826-34; PMID:22182509; http://dx.doi.org/10.1016/j.cellsig.2011.12.005
66. Tekletsadik YK, Sonn R, Osman MA. A conserved role of IQGAP1 in regulating TOR complex 1. J Cell Sci 2012; 125:2041-52; PMID:22328503; http://dx.doi.org/10.1242/jcs.098947
67. White CD, Khurana H, Gnatenko DV, Li Z, Odze RD, Sacks DB, Schmidt VA. IQGAP1 and IQGAP2 are reciprocally altered in hepatocellular carcinoma. BMC Gastroenterol 2010; 10:125; PMID:20977743; http://dx.doi.org/10.1186/1471-230X- 10-125
68. White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009; 583:1817-24; PMID:19433088; http://dx.doi.org/10.1016/j.febslet.2009.05.007
69. Xie Y, Yan J, Cutz JC, Rybak AP, He L, Wei F, Kapoor A, Schmidt VA, Tao L, Tang D. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis. Biochim Biophys Acta 2012; 1822:875-84; PMID:22406297; http://dx.doi.org/10. 1016/j.bbadis.2012.02.019
70. Brill S, Li S, Lyman CW, Church DM, Wasmuth JJ, Weissbach L, Bernards A, Snijders AJ. The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol 1996; 16:4869-78; PMID:8756646
71. Schmidt VA, Scudder L, Devoe CE, Bernards A, Cupit LD, Bahou WF. IQGAP2 functions as a GTP-dependent effector protein in thrombininduced platelet cytoskeletal reorganization. Blood 2003; 101:3021-8; PMID:12515716; http://dx.doi.org/10.1182/blood-2002-09-2807
72. Wang S, Watanabe T, Noritake J, Fukata M, Yoshimura T, Itoh N, Harada T, Nakagawa M, Matsuura Y, Arimura N, et al. IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth. J Cell Sci 2007; 120:567-77; PMID:17244649; http://dx.doi.org/10.1242/jcs.03356
73. Derycke L, Stove C, Vercoutter-Edouart AS, De Wever O, Dollé L, Colpaert N, Depypere H, Michalski JC, Bracke M. The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol 2011; 55:835-40; PMID:22161839; http://dx.doi.org/10.1387/ijdb.113336ld
74. Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, Xue Z, Dou W, Hu F, Wu K, et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One 2011; 6:e18409; PMID:21533124; http://dx.doi.org/10.1371/journal. pone.0018409
75. Xia ZK, Yuan YC, Yin N, Yin BL, Tan ZP, Hu YR. Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer. Dis Esophagus 2012; 25:427-36; PMID:21951916; http://dx.doi.org/10.1111/j.1442-2050.2011. 01261.x
76. Bedrin MS, Abolafia CM, Thompson JF. Cytoskeletal association of epidermal growth factor receptor and associated signaling proteins is regulated by cell density in IEC-6 intestinal cells. J Cell Physiol 1997; 172:126-36; PMID:9207933; http://dx.doi.org/10.1002/(SICI)1097-4652(199707)172:13.0.CO;2-A
77. Chiu HC, Chang TY, Huang CT, Chao YS, Hsu JT. EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells. Mol Oncol 2012; 6:299-310; PMID:22366308; http://dx.doi.org/10.1016/j.molonc.2012.02.001
78. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, et al. Activation of multiple protooncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011; 144:703-18; PMID:21376233; http://dx.doi.org/10.1016/j.cell.2011.02.003
79. Kozma SC, Bogaard ME, Buser K, Saurer SM, Bos JL, Groner B, Hynes NE. The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res 1987; 15:5963-71; PMID:3627975; http://dx.doi.org/10.1093/nar/15.15.5963
80. Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA. IQGAP1 scaffold- kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 2013; 19:626-30; PMID:23603816; http://dx.doi.org/10.1038/nm.3165
81. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902
82. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, et al.; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year followup of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013; 14:72-80; PMID:23246022; http://dx.doi.org/10.1016/S1470-2045(12)70525-9
83. Montanari M, Fabbri F, Rondini E, Frassineti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, Cruciani G. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori 2012; 98:696-701; PMID:23389354
84. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7:214-20; PMID:22758622; http://dx.doi.org/10.2174/157340311799960645
85. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 2013; PMID:23494977; http://dx.doi.org/10.1002/med. 21280
86. Brideau C, Gunter B, Pikounis B, Liaw A. Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 2003; 8:634-47; PMID:14711389; http://dx.doi.org/10.1177/1087057103258285
87. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hählen K, Van Wering ER. Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995; 19:175-81; PMID:7700079; http://dx.doi.org/10.1016/ 0145-2126(94)00126-U
88. Valeriote F, Lin Hs. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 1975; 59:895-900; PMID:1203896
89. Sondak VK, Korn EL, Kern DH. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning 1988; 6:378-91; PMID:3230328; http://dx.doi.org/10.1002/stem.5530060603
90. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4:1798-806; PMID:20010931; http://dx.doi.org/10.1038/nprot.2009.191
91. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9:671-5; PMID:22930834; http://dx.doi.org/10. 1038/nmeth.2089